GlassScriptPhysician profile
Kari Jean Ewalt
NPI 1962559682
$30,500.19
in general payments reported to CMS, 2019-2025
24 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $253 · 2023: $6,901 · 2024: $11K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $4,647 · Honoraria: $2,300 · Consulting Fee: $960 · Education: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,041.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,850.00 |
| Travel and Lodging | $4,647.25 |
| Honoraria | $2,300.00 |
| Consulting Fee | $960.00 |
| Education | $449.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16,763.25 | 2023-2025 | Krystexxa, Enbrel, Tavneos |
| Horizon Therapeutics Plc | $4,528.23 | 2022-2023 | Krystexxa |
| Ucb, INC. | $2,442.29 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $2,116.84 | 2023-2025 | |
| Janssen Biotech, INC. | $1,520.37 | 2022-2025 | Tremfya, Simponi Aria |
| Genzyme Corporation | $681.88 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $668.84 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $386.51 | 2022-2025 | Orencia |
| Lilly USA, LLC | $327.99 | 2022-2025 | Taltz, Zepbound |
| Sandoz INC. | $153.03 | 2023-2025 | Hyrimoz, Jubbonti |
| Janssen Scientific Affairs, LLC | $141.29 | 2022-2023 | Tremfya |
| Pfizer INC. | $138.10 | 2023-2025 | |
| Glaxosmithkline, LLC. | $125.59 | 2023-2025 | Benlysta |
| Sanofi-Aventis U.S. LLC | $81.20 | 2023 | |
| Fresenius Kabi USA, LLC | $79.04 | 2024-2025 | Idacio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $68.73 | 2023-2025 | Hadlima, Renflexis |
| Astrazeneca Pharmaceuticals LP | $67.03 | 2024-2025 | Saphnelo |
| Genentech USA, INC. | $62.69 | 2024-2025 | Actemra, Gazyva |
| Aurinia Pharma U.S., INC. | $45.43 | 2023-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $26.25 | 2025 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $23.72 | 2024 | Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.00 | 2023 | Cyltezo |
| Arcutis Biotherapeutics, INC. | $15.20 | 2023 | |
| Invivyd INC | $14.69 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Ewalt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.